Key Highlights

  • UroGen Pharma closed up 16.31% at $46.43 on August 5, a fresh 52-week high.
  • Second-quarter revenue reached $72.5 million versus consensus estimates of roughly $63.5 million, a 14.02% beat.
  • Adjusted EPS loss of $0.28 beat the expected $0.38 loss by 26.32%.
  • ZUSDURI generated $50.4 million in second-quarter revenue, up 73% sequentially from $21.7 million in the first quarter.
  • Management raised full-year 2026 JELMYTO revenue guidance to $97 million to $101 million and reaffirmed 2025 continued growth guidance.

What Happened

UroGen Pharma (NASDAQ:URGN) is a Princeton, New Jersey-based biotechnology company focused on developing and commercializing innovative solutions for urothelial and specialty cancers, leveraging its proprietary RTGel reverse-thermal hydrogel technology platform. The company's commercial portfolio includes JELMYTO, the first and only FDA-approved non-surgical treatment for low-grade upper tract urothelial carcinoma, and ZUSDURI, the first treatment approved for adults with recurrent low-grade, intermediate-risk non-muscle invasive bladder cancer.

Shares closed at a fresh 52-week high on August 5 after the company crushed second-quarter expectations, reporting revenue of $72.5 million versus consensus estimates of roughly $63.5 million, a 14.02% beat, driven by accelerating adoption of bladder cancer therapy ZUSDURI, which generated $50.4 million in sales, up 73% sequentially from the first quarter.

Operating Metrics Show Accelerating Adoption

Activated accounts rose to 1,444 from 972 in the first quarter, unique prescribers climbed to 452 from 256, and repeat prescribers nearly doubled to 204, representing about 45% of writers, up from roughly 40% in the first quarter. Community urology practices, which represent about 70% of the addressable market, accounted for approximately 55% of utilization, reinforcing management's confidence that the drug's launch trajectory is accelerating faster than expected.

Management raised full-year operating expense guidance, reaffirmed JELMYTO revenue guidance of $97 million to $101 million for 2026, and highlighted pipeline progress including an on-track Q3 UGN-103 NDA submission and a planned Q4 Phase 1 study start for UGN-501. The stock is extending a powerful multi-month rally, up more than 100% since April, as investors reward ZUSDURI's launch trajectory and expanding patent protection into 2044.

Balance Sheet Improvements

Second-quarter research and development expenses were $17.3 million, down from $18.9 million a year ago, while SG&A expenses were $48.6 million, up from $43.2 million. Net loss was $14.4 million, or $0.28 per diluted share, an improvement from $49.9 million, or $1.05 per share, in the same quarter last year. Cash, cash equivalents, and marketable securities totaled $108.0 million as of June 30, 2026.

Conclusion

UroGen's second-quarter results confirm ZUSDURI's launch trajectory is exceeding internal and external expectations, with prescriber and account growth data suggesting durable adoption beyond early users. Today's close at fresh 52-week highs reflects growing investor confidence that this growth phase, supported by strengthening patent protection and an expanding pipeline, has substantial room to continue into 2027.

This article is for informational purposes only and does not constitute investment advice. Readers should conduct their own research before making financial decisions.